General Information of Drug (ID: DMYDW6J)

Drug Name
PGD2 Drug Info
Synonyms
Prostaglandin D2; prostaglandin D2; 11-Dehydroprostaglandin F2-alpha; 41598-07-6; BRN 2170623; UNII-RXY07S6CZ2; 11-Dehydroprostaglandin F2alpha; RXY07S6CZ2; CHEBI:15555; (5Z,13E,15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; (5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; 9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid; [3H]PGD2; (5E,13E)-9,15-DIHYDROXY-11-OXOPROSTA-5,13-DIEN-1-OIC ACID; Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5Z,9-alpha,13E,15S)-; 11-dehydroprostaglandin F2-alpha
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
448457
ChEBI ID
CHEBI:15555
CAS Number
CAS 41598-07-6
TTD Drug ID
DMYDW6J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AS-013 DMD7XWS Thrombosis DB61-GB90 Phase 3 [16]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [6]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [17]
ZD6416 DM46JIR Pain MG30-MG3Z Discontinued in Phase 2 [18]
ONO-8130 DMBDCL4 Pollakiuria MF50.1 Terminated [19]
ONO-8711 DM2VRK7 Pain MG30-MG3Z Terminated [20]
U46619 DM13FX4 Discovery agent N.A. Investigative [6]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [21]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [7]
cicaprost DM7ZJ4H Discovery agent N.A. Investigative [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [22]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [23]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [24]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [25]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
E7046 DMFVT43 Rectal adenocarcinoma 2B92 Phase 1 [27]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [28]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [27]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [29]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [17]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [30]
Alprostadil DMWH7NQ Aorta coarctation Approved [31]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [32]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [33]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [34]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [35]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [36]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [34]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [37]
Fevipiprant DM4NX0C Asthma CA23 Phase 3 [38]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [3]
AMG 853 DM973N4 Asthma CA23 Phase 2 [39]
ADC-3680 DM8GHIX Allergic rhinitis CA08.0 Phase 2 [40]
ARRY-502 DM17469 Allergic asthma CA23.0 Phase 2 [41]
QAV-680 DMIZYV1 Allergic rhinitis CA08.0 Phase 2 [42]
AP-761 DMISQOZ Asthma CA23 Phase 2 [43]
AZD1981 DMMCL9F Chronic obstructive pulmonary disease CA22 Phase 2 [44]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [34]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [45]
QAW-039 DMPCFXN Asthma CA23 Phase 3 [46]
AMG 853 DM973N4 Asthma CA23 Phase 2 [39]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [47]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [48]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [49]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [40]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [50]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [51]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [17]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [52]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [53]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [54]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [55]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [56]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [34]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [57]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [58]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [59]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [7]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [58]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [7]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [17]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [60]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [61]
U46619 DM13FX4 Discovery agent N.A. Investigative [21]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [7]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [21]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Poly polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [62]
Gefitinib DM15F0X Colon adenocarcinoma Approved [63]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [64]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [65]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [66]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [67]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [66]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [68]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [69]
Methotrexate DM2TEOL Anterior urethra cancer Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caspase-3 (CASP3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [71]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [72]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [73]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [74]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [75]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [76]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [77]
Mannitol DMSCDY9 Bronchiectasis CA24 Approved [78]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [79]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [81]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [82]
Quercetin DM3NC4M Obesity 5B81 Approved [83]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [84]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [82]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [85]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [86]
Leflunomide DMR8ONJ Arthritis FA20 Approved [87]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [88]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [13]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [90]
Quercetin DM3NC4M Obesity 5B81 Approved [91]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [92]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [93]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [94]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [95]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [96]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [97]
Stavudine DM6DEK9 Human immunodeficiency virus infection 1C62 Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Thyroglobulin (TG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [99]
Propylthiouracil DM6D7N8 Hyperthyroidism 5A02 Approved [100]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [101]
Testosterone DM7HUNW Hot flushes GA30 Approved [102]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [102]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [103]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [101]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [88]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [104]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [105]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [83]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [106]
Fructose DM43AN2 Vomiting MD90 Approved [107]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [108]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [109]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [86]
Ketotifen DM74XKS Allergic conjunctivitis 9A60.02 Approved [110]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [14]
Leflunomide DMR8ONJ Arthritis FA20 Approved [87]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [111]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [112]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [113]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [105]
Arsenic DMTL2Y1 N. A. N. A. Approved [114]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [115]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [116]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [8]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Interleukin-1 beta (IL1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [117]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [118]
Gefitinib DM15F0X Colon adenocarcinoma Approved [119]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [120]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [121]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [120]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [122]
Selenium DM25CGV N. A. N. A. Approved [123]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [124]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [125]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [126]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [127]
Fructose DM43AN2 Vomiting MD90 Approved [128]
Ketoprofen DMRKXPT Bursitis Approved [128]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [129]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [130]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [131]
Gefitinib DM15F0X Colon adenocarcinoma Approved [132]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [133]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [134]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [135]
Selenium DM25CGV N. A. N. A. Approved [111]
Methotrexate DM2TEOL Anterior urethra cancer Approved [81]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [136]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [137]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [138]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [139]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [140]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [86]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [141]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [115]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [142]
Diazepam DM08E9O Alcohol withdrawal Approved [143]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [144]
Desogestrel DM27U4Y Contraception QA21 Approved [144]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [142]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [142]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [145]
Quercetin DM3NC4M Obesity 5B81 Approved [146]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [99]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Agonist [2]
Prostaglandin D2 receptor 2 (PTGDR2) TTQDMX5 PD2R2_HUMAN Agonist [3]
Prostaglandin E2 receptor EP1 (PTGER1) TTG1QMU PE2R1_HUMAN Agonist [4]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Agonist [5]
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Agonist [6]
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Agonist [6]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Agonist [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acyl-protein thioesterase 2 (LYPLA2) OT03UIYC LYPA2_HUMAN Biotransformations [8]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Regulation of Drug Effects [9]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Regulation of Drug Effects [10]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Regulation of Drug Effects [12]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Protein Interaction/Cellular Processes [13]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Gene/Protein Processing [14]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Protein Interaction/Cellular Processes [11]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Protein Interaction/Cellular Processes [11]
Thyroglobulin (TG) OT3ELHIJ THYG_HUMAN Gene/Protein Processing [15]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1891).
2 A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15.
3 CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
4 Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
5 Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
6 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
7 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
8 Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. J Biol Chem. 2014 Dec 5;289(49):33741-53. doi: 10.1074/jbc.M114.582353. Epub 2014 Oct 9.
9 Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):177-87. doi: 10.1016/j.jsbmb.2009.12.009. Epub 2009 Dec 28.
10 Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis. 2016 Jun 23;2:16012. doi: 10.1038/npjamd.2016.12. eCollection 2016.
11 Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta. 2005 Apr 15;1743(3):291-304.
12 Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells. J Neuroinflammation. 2009 Sep 14;6:26.
13 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
14 A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
15 15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1859-69. doi: 10.1152/ajpcell.2000.279.6.C1859.
16 Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
17 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
18 The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
19 ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
20 Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
21 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
22 Clinical pipeline report, company report or official report of Avarx.
23 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
24 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
25 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
26 Clinical pipeline report, company report or official report of Tempest Therapeutics.
27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
29 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
31 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
32 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
33 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
34 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
35 Pfizer. Product Development Pipeline. March 31 2009.
36 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
37 Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
38 Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
39 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
40 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
41 Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
42 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
44 Clinical pipeline report, company report or official report of AstraZeneca (2009).
45 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
46 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
47 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
48 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
49 Clinical pipeline report, company report or official report of Shionogi (2011).
50 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
51 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
52 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
53 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
55 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
56 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
57 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
58 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
59 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
60 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
61 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
62 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
63 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
64 Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
65 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
66 The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
67 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
68 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
69 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
70 Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
71 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
72 [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
73 Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
74 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
75 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
76 Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
77 Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
78 Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
79 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
80 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
81 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
82 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
83 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
84 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
85 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
86 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
87 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
88 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
89 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
90 Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
91 The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
92 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
93 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
94 Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
95 Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
96 Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
97 Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
98 Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
99 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
100 Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
101 Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab. 2005 Oct;90(10):5663-71. doi: 10.1210/jc.2005-0367. Epub 2005 Jul 19.
102 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
103 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6. doi: 10.1210/jc.2002-021834.
104 Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007 Dec;17(12):1189-200. doi: 10.1089/thy.2007.0215.
105 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
106 Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
107 Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
108 Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
109 AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
110 Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
111 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
112 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
113 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
114 Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
115 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
116 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
117 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
118 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
119 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
120 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
121 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
122 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
123 Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
124 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
125 Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
126 Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
127 A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
128 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
129 CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
130 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
131 Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
132 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
133 Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
134 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
135 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
136 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
137 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
138 Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
139 Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
140 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
141 Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
142 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
143 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
144 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
145 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
146 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.